talquetamab + carfilzomib

Talquetamab + carfilzomib is an experimental combination therapy under investigation for the treatment of multiple myeloma. **Talquetamab** is a bispecific monoclonal antibody that binds to GPRC5D on myeloma cells and CD3 on T-cells, redirecting cytotoxic T lymphocytes to kill tumor cells. **Carfilzomib** is a selective proteasome inhibitor that induces apoptosis in myeloma cells by blocking protein degradation pathways. This combination is currently in early-phase clinical trials to assess safety, dosing, and efficacy in relapsed or refractory multiple myeloma patients, particularly those with prior exposure to multiple classes of myeloma therapy[1][3][5].

Other names

talquetamab + carfilzomibtalquetamab-tgvs + carfilzomib